Denali Therapeutics GAAP EPS of -$0.86

• Denali Therapeutics press release (NASDAQ:DNLI): Q4 GAAP EPS of -$0.86.

• Cash, cash equivalents, and marketable securities were approximately $1.03 billion as of December 31, 2023.

More on Denali Therapeutics

• Diving Into Denali Therapeutics
• Denali slips as Sanofi fails in mid-stage trial for ALS therapy
• Citi starts Denali at buy, sees catalyst-rich window starting in 2024
• Seeking Alpha’s Quant Rating on Denali Therapeutics
• Historical earnings data for Denali Therapeutics